This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
Information on how to access Cibinqo®▼ (abrocitinib) prescribing information and adverse event reporting can be found at the bottom of the page.
Updated Safety Recommendation - Abrocitinib should only be used if no suitable treatment alternatives are available in patients: 65 years of age and older, patients with a history of atherosclerotic cardiovascular disease or other cardiovascular risk factors (such as current or past long-time smokers), patients with malignancy risk factors (e.g. current malignancy or a history of malignancy). (Cibinqo Summary of Product Characteristics)
Read the JADE DARE and JADE EXTEND studies here:
JADE DARE evaluated the efficacy and safety of CIBINQO vs dupilumab (both in combination with medicated topical therapy) in 727 patients with moderate-to-severe AD.7
Assessments during first 12 weeks of JADE EXTEND: IGA, EASI, PP-NRS and DLQI; data were reported as observed; no imputation was made for missing data. Efficacy analyses were descriptive in nature with no formal hypothesis testing but with 95% CIs reported.1
*Patients randomised to dupilumab received a loading dose of 600 mg.7 †Topical therapy includes low- to medium-potency topical corticosteroids and other medicated topicals, which were required per study protocol.7 ‡±Topical therapy includes topical corticosteroids and other medicated topicals, which were used as needed per usual practice.1
Outcomes at Week 12 after CIBINQO 200 mg initiation in patients who had received dupilumab for 26 weeks in JADE DARE.1
Example
Adapted from Silverberg JI, et al. 2025 and Pfizer Ltd. Data on File.1–5
Data limitations: short-term (12 weeks) post hoc analysis with limited patient population. CIs were based on normal approximation and P values were not calculated1
Read the safety information about abrocitinib
Learn more about flexible dosing in patients on Cibinqo
References
1. Silverberg JI, et al. Dermatol Ther (Heidlb). 2025;15(2):367–380.
2. Pfizer Ltd. Data on File: REF-CIB4002, Cibinqo (abrocitinib) JADE DARE-EXTEND (NCT03422822). Week 12 Dupilumab responder patient outcomes (EASI-50, EASI-75, EASI-90).
3. Pfizer Ltd. Data on File: REF-CIB3997, Cibinqo (abrocitinib) JADE DARE-EXTEND (NCT03422822). Week 12 Dupilumab responder patient outcomes (PP-NRS0/1, PP-NRS4).
4. Pfizer Ltd. Data on File: REF-CIB4004, Cibinqo (abrocitinib) JADE DARE-EXTEND (NCT03422822). Week 12 Dupilumab non-responder patient outcomes (EASI-50, EASI-75, EASI-90).
5. Pfizer Ltd. Data on File: REF-CIB4005, Cibinqo (abrocitinib) JADE DARE-EXTEND (NCT03422822). Week 12 Dupilumab non-responder patient outcomes (PP-NRS0/1, PP-NRS4).
6. ClinicalTrials.gov. NCT03422822. Available at: https://www.clinicaltrials.gov/ct2/show/NCT03422822. Accessed May 2025.
7. Reich K, et al. Lancet. 2022;400(10348):273–282.
Cibinqo Risk Minimisation Programme (RMP) materials, including a Patient Card and Prescriber Brochure, are available from https://www.medicines.org.uk/emc/product/12874/rmms. Patients treated with Cibinqo should be given the Patient Card.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2025 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024.